Cancers emerge from an ongoing Darwinian evolutionary process, often leading to multiple competing subclones within a single primary tumour. This evolutionary process culminates in the formation of metastases, which is the cause of 90% of cancer-related deaths. However, despite its clinical importance, little is known about the principles governing the dissemination of cancer cells to distant organs. Although the hypothesis that each metastasis originates from a single tumour cell is generally supported, recent studies using mouse models of cancer demonstrated the existence of polyclonal seeding from and interclonal cooperation between multiple subclones. Here we sought definitive evidence for the existence of polyclonal seeding in human malignancy and to establish the clonal relationship among different metastases in the context of androgen-deprived metastatic prostate cancer. Using whole-genome sequencing, we characterized multiple metastases arising from prostate tumours in ten patients. Integrated analyses of subclonal architecture revealed the patterns of metastatic spread in unprecedented detail. Metastasis-to-metastasis spread was found to be common, either through de novo monoclonal seeding of daughter metastases or, in five cases, through the transfer of multiple tumour clones between metastatic sites. Lesions affecting tumour suppressor genes usually occur as single events, whereas mutations in genes involved in androgen receptor signalling commonly involve multiple, convergent events in different metastases. Our results elucidate in detail the complex patterns of metastatic spread and further our understanding of the development of resistance to androgen-deprivation therapy in prostate cancer.
Nature. 2015 Apr 16;520(7547):353-357. doi: 10.1038/nature14347 Q148.52025
The evolutionary history of lethal metastatic prostate cancer
致命性转移性前列腺癌的进化历史 翻译改进
作者单位 +展开
作者单位
DOI: 10.1038/nature14347 PMID: 25830880
摘要 Ai翻译
相关内容
-
Commentary on "The evolutionary history of lethal metastatic prostate cancer." Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker
评论:致命性转移性前列腺癌的进化历史
Urologic oncology. 2016 Nov;34(11):520-521.
-
Author Correction: The evolutionary history of lethal metastatic prostate cancer
《致命转移性前列腺癌的进化史》作者更正通知
Nature. 2020 Aug;584(7820):E18.
-
The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer
初诊转移性前列腺癌患者首次随访时前列腺特异性抗原半衰期的预后影响
Urologic oncology. 2015 Sep;33(9):383.e17-22.
-
Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report
抗雄激素撤药综合征长期完全缓解一例转移性前列腺癌患者的报告
Molecular and clinical oncology. 2016 Sep;5(3):208-210.
-
Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer
连续与间歇内分泌治疗转移性前列腺癌的meta分析及试验序贯分析
Urologic oncology. 2013 Jul;31(5):549-56.
-
Stereotactic ablative radiation therapy in metastatic prostate cancer
转移性前列腺癌的立体定向消融放疗
Current opinion in oncology. 2024 May 1;36(3):180-185.
-
Metastatic Prostate Cancer
转移性前列腺癌
The New England journal of medicine. 2018 Feb 15;378(7):645-657.
-
[The natural history of metastatic prostate cancer]
转移性前列腺癌的自然史
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2008 Nov:18 Suppl 7:S327-31.